Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges

Behzadi, F and Raeisi, M and Nouri Vaskeh, M and Danandeh Mehr, A and Askari, E and Roosta, Y (2021) Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges. Leukemia Research Reports, 15. pp. 1-7.

[thumbnail of 2224.pdf]
Preview
Text
2224.pdf

Download (972kB) | Preview

Abstract

A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations
regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and
COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interaction between CLL and
COVID-19 remains a major challenge. Also, CLL patients have a lower rate of anti-SARS-CoV-2 IgG development.
Evidences show the unacceptable therapeutic outcome in these patients. Although the CLL-COVID-19 occurrence
is associated with adverse clinical consequences, no general and standard agreement has yet been presented for
the management and treatment of this disease

Item Type: Article
Uncontrolled Keywords: Chronic lymphocytic leukemia COVID-19 Diagnosis Prevalence Treatment
Subjects: R Medicine > R Medicine (General)
Depositing User: Unnamed user with email gholipour.s@umsu.ac.ir
Date Deposited: 02 Jun 2021 04:38
Last Modified: 02 Jun 2021 04:38
URI: https://eprints.umsu.ac.ir/id/eprint/6230

Actions (login required)

View Item
View Item